Sino Biopharmaceutical Limited announced that the latest results of phase II clinical study (NCT05383898) of KRAS G12C Inhibitor "Garsorasib Tablet (D-1553)", which is jointly developed by the Group, will be presented at the Annual Meeting 2024 of American Association for Cancer Research, for the treatment of patient with non-small cell lung cancer ("NSCLC") with KRAS G12C mutation. Title of abstract: Open-label, single-arm, multicenter, phase 2 trial of garsorasib in KRAS G12C-mutated non-small-cell lung cancer.
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
2.77 HKD | +1.09% | +18.38% | -20.17% |
Apr. 25 | Sino Biopharm Completes Phase I Study of Hepatitis B Drug | MT |
Apr. 22 | Lull in Geopolitical Tensions Lifts Asian Stock Markets | MT |
EPS Revisions
1st Jan change | Capi. | |
---|---|---|
-20.17% | 6.49B | |
+25.83% | 661B | |
+27.00% | 566B | |
-6.76% | 352B | |
+20.34% | 332B | |
+3.00% | 283B | |
+13.09% | 231B | |
+5.46% | 200B | |
-9.61% | 195B | |
-6.26% | 145B |
- Stock Market
- Equities
- 1177 Stock
- News Sino Biopharmaceutical Limited
- Sino Biopharmaceutical Limited Announces Latest Results of Phase II Clinical Study of KRAS G12C Inhibitor Garsorasib Tablet